Jing Li

机构：Shandong University of Traditional Chinese Medicine, Sun Yat-sen University, Fudan University, Xi'an Medical University, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Xian Yang Central Hospital, First Affiliated Hospital Zhejiang University, Intercept Pharmaceuticals (United States) · ORCID：0000-0001-9187-7809

发表论文 287 篇 · 总被引 4457 次 · h-index 35

代表论文

• The multifaceted roles of apolipoprotein E4 in Alzheimer’s disease pathology and potential therapeutic strategies (2025 · Cell Death Discovery · 被引 36)
• Improving the clinical trial environment and infrastructure: moving from global resolution to action (2025 · The Lancet Global Health · 被引 8)
• Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0–1 DLBCL patients (2025 · Annals of Hematology · 被引 3)
• Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma (2025 · Blood · 被引 2)
• Alterations in the Gut Microbiota of Patients with Esophageal Squamous Cell Carcinoma: A Cross-Sectional Study Conducted in a High-Incidence Region of China (2025 · International Journal of General Medicine · 被引 2)
• Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study (2026 · Journal of Comparative Effectiveness Research · 被引 1)